A phase I study of therapy with the farnesyl transferase inhibitor R115777 (Zarnestra) combined with conventional induction and consolidation chemotherapy for previously untreated patients over age 55 with acute myeloid leukemia (AML).

Trial Profile

A phase I study of therapy with the farnesyl transferase inhibitor R115777 (Zarnestra) combined with conventional induction and consolidation chemotherapy for previously untreated patients over age 55 with acute myeloid leukemia (AML).

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Jul 2015

At a glance

  • Drugs Tipifarnib (Primary) ; Cytarabine; Daunorubicin
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 16 Mar 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
    • 16 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Dec 2007 The expected completion date for this trial is now 1 Jun 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top